#earnings paradox

5 AI perspectives

The Money Wasn't From Selling Hard Drives — The Real Story Behind WDC's Record EPS

Western Digital's Q4 FY2026 results delivered revenue of $3,747M (+44% Y/Y), a record non-GAAP gross margin of 54.4%, and non-GAAP EPS of $3.56 (+109%), beating market consensus on every metric. However, the headline FY26 GAAP EPS of $24.28 conceals a critical structural detail: of the $9,424M in GAAP net income, $6,498M represents non-cash fair value gains on WDC's retained SanDisk stake — earnings entirely unrelated to shipping hard drives. The stock's approximately 11% post-earnings drop traced directly to Q1 FY27 gross margin guidance of 55–56%, which fell short of the elevated industry benchmark set by competitor Seagate. Beneath that guidance gap lies an approximately one-year technology timing difference — Seagate's 44TB HAMR drives are already shipping at volume to hyperscalers, while WDC's HAMR shipment target remains H1 2027. Whether WDC's deliberate choice to delay HAMR while maximizing ePMR UltraSMR margins is a rational capital allocation strategy or a costly market share concession to Seagate is the defining investment question for this stock.

8/13/2026

Economy

Eli Lilly Posted $23B in Revenue. So Why Did the Stock Fall? The Answer Is $3.03.

Eli Lilly (NYSE: LLY) delivered Q2 2026 revenue of $22,974M — a 48% year-over-year increase — while non-GAAP EPS rose 33% to $8.38 and the company raised its full-year revenue guidance to $85.0B–$87.0B, results that by any conventional measure should have sent shares higher. Instead, LLY fell on the day of the announcement, and the explanation lives inside a single accounting line: $3.03 per share in acquired in-process research and development (IPR&D) expenses, representing $2.8B charged from the acquisitions of Orna Therapeutics, Ajax Therapeutics, Kelonia, and Centessa. This charge more than offset management's $2.78 midpoint raise to underlying non-GAAP EPS guidance, producing a paradox where the fundamental business outlook improved yet the final 2026 EPS guidance range settled lower at $35.50–$36.50. Global volumes surged 60% but net realized prices fell 13% globally, with international markets absorbing a 36% price collapse driven primarily by Mounjaro's entry into China's National Reimbursement Drug List — a mechanism distinct from a traditional price war and potentially exportable to other large markets. The Mounjaro-Zepbound duo generated roughly $14.87B in combined quarterly revenue — approximately 65% of total sales — creating a concentration risk that compounds the pricing concern. Novo Nordisk shares also fell roughly 5% on the same day the Danish drugmaker reported near-stagnant full-year guidance of 0% to minus 6%, suggesting the market is repricing the GLP-1 category as a whole rather than any single company's quarter. Retatrutide's planned Q1 2027 BLA submission across three indications and the additional $4.5B Indiana manufacturing commitment are the pivotal variables that will ultimately determine whether Lilly's aggressive invest-while-growing model justifies the premium it commands.

8/8/2026

Economy

Record Quarter, Record Crash — I Think Adidas CEO Björn Gulden Made the Right Bet

Adidas AG (ADS, Xetra) delivered record Q2 2026 net sales of €6.74 billion, representing 14% currency-neutral growth driven by approximately 18 million jersey sales during the FIFA World Cup in which both finalists wore Adidas kits — yet the stock collapsed 18.7% on the same day, marking the steepest single-session decline since the company's 1995 Frankfurt listing. The selloff was triggered by EBIT of €574 million missing the €623 million consensus, a surge in marketing and point-of-sale expenditure to €924 million (13.7% of net sales, €212 million above plan), and management's decision to hold the full-year EBIT guidance flat at approximately €2.3 billion despite raising revenue guidance to 9–10% currency-neutral growth. Key positives include a gross margin of 52.5% (up 0.8 percentage points year-over-year), DTC share at 57% with 25% DTC growth, Performance division growth of 39%, Apparel growth of 35%, and an undisclosed $250–300 million in potential tariff refunds not yet incorporated into guidance — alongside JPMorgan's maintained Overweight and €230 price target as of August 1, 2026. Structural uncertainties include whether the elevated marketing spend reflects a one-time World Cup investment or a permanent DTC-driven cost increase, CFO succession risk as Harm Ohlmeyer exits and Birgit Kretschmer formally assumes the role on January 1, 2027, and H2 base effects following the World Cup demand surge. The central argument presented here is that the market's reaction constitutes an overreaction to a one-time event, and that CEO Björn Gulden's aggressive brand investment during the World Cup was strategically justified given the brand's turnaround trajectory, Nike's concurrent revenue stagnation at $46.4 billion flat, and the strength of Adidas's underlying product economics.

8/4/2026

Economy

A record $695B backlog, the FAA's blessing returned — so why is Boeing stock still sinking?

Boeing reports second-quarter 2026 results on Tuesday, July 28, and the setup heading into that call is genuinely strange. The company delivered 314 commercial jets in the first half of the year, its best six-month stretch since 2018, and its total backlog climbed to a record $695 billion covering more than 6,100 airplanes. Eight days before the earnings release, the Federal Aviation Administration handed Boeing back full authority to issue airworthiness certificates for every 737 MAX and 787 it builds, reversing a restriction imposed in 2019 after the Lion Air and Ethiopian Airlines crashes and extended to the 787 in 2022. Yet the stock closed at $205.90 on July 22, below its 20-, 50-, 100- and 200-day moving averages, while first-quarter free cash flow ran to negative $1.45 billion. The gap between the good news and the price action traces back to a cash cushion that shrank 29% in a single quarter, a $1 billion annual drag from the Spirit AeroSystems integration, and the uncomfortable fact that peak delivery pressure and reduced final-stage regulatory scrutiny have arrived in the same month.

7/31/2026

Economy

Record AI Revenue, Cratering Stock: Broadcom Just Exposed the Incurable Disease of AI Investing

Broadcom (AVGO) delivered fiscal Q2 2026 results featuring $10.8 billion in AI semiconductor revenue — a 143% year-over-year surge representing the highest AI revenue growth rate in the global semiconductor industry outside of Nvidia. Total quarterly revenue of $22.19 billion, adjusted EPS of $2.44 beating the Wall Street consensus of $2.40, and an AI backlog of $73 billion collectively signal extraordinary execution by any rational metric. Yet shares plunged 8–14% in after-hours trading, triggered primarily by a $140 million VMware software revenue shortfall — less than 2% of total sales — and a Q3 AI guidance of $16 billion that fell short of the most aggressive analyst models. This paradox directly exposes a structural identity crisis: with AI comprising 49% of revenue, markets have still not reclassified Broadcom as a pure-play AI stock, leaving it in a valuation purgatory that is simultaneously a persistent risk and a latent opportunity for investors who can see past the noise. The incident transcends individual company performance to serve as a stark warning that expectations inflation in the 2026 AI equity market has passed a critical threshold — markets are no longer rewarding companies for what they achieve, but punishing them for failing to promise enough about what comes next.

6/5/2026